Olaparib combined with an ATR or Chk1 inhibitor as a treatment strategy for acquired olaparib-resistant BRCA1 mutant ovarian cells

Brian T. Burgess, Abigail M. Anderson, J. Robert McCorkle, Jianrong Wu, Frederick R. Ueland, Jill M. Kolesar

Research output: Contribution to journalArticlepeer-review

34 Scopus citations

Fingerprint

Dive into the research topics of 'Olaparib combined with an ATR or Chk1 inhibitor as a treatment strategy for acquired olaparib-resistant BRCA1 mutant ovarian cells'. Together they form a unique fingerprint.

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science